Table 1.
Characteristics of the Participants at Baseline
| Intent to Treat Group | Overall (N=48) | Intervention group (n1=26) | Control group (n2=22) |
|---|---|---|---|
|
| |||
| Characteristic | Mean±SD(Range) or N(%) | Mean±SD(Range) or n1(%) | Mean±SD(Range) or n2(%) |
| Oral aperture at baseline (mm) | 36.5±9.7 (10.0–56.7) | 36.2±11.0 (10.0–56.7) | 36.8±8.0 (22.7–50.3) |
| Age (years) | 50.7±13.0 (22–76) | 51.9±14.3 (22–76) | 49.2±11.4 (23–73) |
| Disease duration (years)‡1 | 7.6±6.1 (1.0–24.7) | 8.3±6.4 (1.5–24.7) | 6.8±5.8 (1.0–17.8) |
| Female | 38 (79.2%) | 21 (80.8%) | 17 (77.3%) |
| African American§ | 26 (54.2%) | 13 (50.0%) | 13 (59.1%) |
| Diffuse cutaneous subset | 21 (43.8%) | 13 (50.0%) | 8 (36.4%) |
| Calcium channel blocker | 26 (54.2%) | 12 (46.2%) | 14 (63.3%) |
| Immunosuppressant | 11 (22.9%) | 8 (30.8%) | 3 (13.6%) |
| Appropriate to Treat Group | Overall (N=28) | Orofacial Exercise group (N=13) | No-exercise group (N=15) |
|---|---|---|---|
|
| |||
| Characteristic | Mean±SD(Range) or N(%) | Mean±SD(Range) or n1(%) | Mean±SD(Range)or n2(%) |
| Oral aperture at baseline (mm) | 30.1±6.7 (10.0–38.3) | 27.4±7.4 (10.0–35.0) | 32.4±5.3 (22.7–38.3)† |
| Age (years) | 51.3±12.3 (23–76) | 51.76±14.09 (23–76) | 50.87±10.93 (31–73) |
| Disease duration (years)‡2 | 8.6±7.1 (1.0–24.7) | 11.3±7.7 (1.5–24.7) | 6.2±5.9 (1.0–17.8) |
| Female | 22 (78.6%) | 11(84.6%) | 11 (73.3%) |
| African American§ | 16 (57.1%) | 7 (53.8%) | 9 (60.0%) |
| Diffuse cutaneous subset | 14 (50.0%) | 8 (61.5%) | 6 (40.0%) |
| Calcium channel blocker | 15 (53.6%) | 5 (38.5%) | 10 (66.7%) |
| Immunosuppressant | 7 (25.0%) | 5 (38.5%) | 2 (13.3%) |
†
P=0.049;
‡1
N=42, due to missing data;
‡2
N=25, due to missing data;
§
Only African Americans and Caucasians.